Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Medications
3.3. Snippet by Chronic Inflammatory Disease Type
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Growing advancements and clinical trials by key players
4.1.1.2. Rising chronic inflammation diseases prevalence
4.1.2. Restraints
4.1.2.1. Side effects of chronic inflammation treatment medications
4.1.3. Opportunity
4.1.3.1. Rising research and development and novel product launches
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Pipeline Anbalysis
5.6. Patent Analysis
5.7. SWOT Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. Nonspecific Proliferative *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Granulomatous Inflammation
7.3.1. Foreign Body Granuloma
7.3.2. Infectious Granuloma
8. By Medications
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
8.1.2. Market Attractiveness Index, By Medications
8.2. Metformin *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Non-steroidal anti-inflammatory drugs (NSAIDs)
8.3.1. Naproxen
8.3.2. Ibuprofen
8.3.3. Aspirin
8.4. Statins
8.4.1. Simvastatin
8.4.2. Rosuvastatin
8.5. Corticosteroids
8.5.1. Cortisone
8.5.2. Prednisone
8.6. Herbal Supplements
9. By Chronic Inflammatory Disease Type
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Chronic Inflammatory Diseases
9.1.2. Market Attractiveness Index, By Chronic Inflammatory Diseases
9.2. Diabetes *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Cardiovascular Diseases
9.4. Arthritis and Joint Diseases
9.5. Chronic Obstructive Pulmonary Disease (COPD)
9.6. Allergies
9.7. Others
10. By Distribution Channel
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.1.2. Market Attractiveness Index, By Distribution Channel
10.2. Hospital Pharmacy *
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Retail Pharmacy
10.4. Online Pharmacy
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Chronic Inflammatory Diseases
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Chronic Inflammatory Diseases
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. U.K.
11.3.7.3. France
11.3.7.4. Spain
11.3.7.5. Italy
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
12.4.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
12.4.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Chronic Inflammatory Diseases
12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.4.5.1. Brazil
12.4.5.2. Argentina
12.4.5.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Chronic Inflammatory Diseases
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Chronic Inflammatory Diseases
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Pfizer Inc. *
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. NodThera
13.3. Abcentra
13.4. Evommune, Inc.
13.5. Sterna biologicals
13.6. Halia Therapeutics, Inc.
13.7. Amgen Inc.
13.8. AstraZeneca
13.9. Takeda Pharmaceutical Company Limited
13.10. Annexon, Inc.
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us